Strategy

Sage will end development for dalzanemdor after it failed in a Phase II Huntington’s disease trial, leaving the company with one commercial drug and three early-stage assets.

The early adoption of artificial intelligence/machine learning has centered around drug discovery, but the technologies are being applied to other fields, including pharma marketing.

With most regions reporting double-digit growth in the second quarter, analysts’ opinions differ about Lupin’s future.

Having previously set itself a deadline of the end of November to strike a licensing deal for one of two biosimilar candidates – or risk failing to meet its working capital requirements – Sweden’s Xbrane has now announced a global licensing partnership with Intas for its nivolumab Opdivo rival, with just days to spare.

The latest campaign from Biosimilars Canada, #SaveBigWithBiosimilars, targets businesses to raise awareness of the benefits of using biosimilars for employee health benefit plans.

Detailed results for CD40L inhibitor dapirolizumab pegol showed consistent improvements over time with meaningful gains over placebo across all endpoints in its first Phase III study.

As it delivered financial first-half results, Japan’s Towa raised its full-year forecast after seeing continued strong demand in Japan and in anticipation of a lower than predicted R&D spend.

Public Company Edition: President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the US Department of Health and Human Services is seen as raising the potential for regulatory risk. Also, Geron revealed up to $375m in royalty and debt financings, while Zai Lab grossed $200m in a FOPO.

Amneal knows what it wants and is determined to get it. With more and more complex products being added to its portfolio, the firm marks another “terrific” quarterly performance.

Reflecting the company’s acquisition of Alimera Sciences, ANI Pharmaceuticals has shared the first results that included new assets as it pushes to a more diversified business strategy.